Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pluri Inc. (PLUR.TA)
Haifa, IL
Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology company dedicated to advancing placenta-derived cell therapies. Its primary goal is to address a spectrum of health issues, including inflammatory conditions, muscle damage, and blood disorders. The company's core development involves placental expanded (PLX) cell products. A leading candidate, PLX-PAD, is currently in a Phase III clinical trial to improve muscle recovery following hip fracture surgery. It is also undergoing a Phase I/II trial, in partnership with Tel Aviv Sourasky Medical Center, for the treatment of steroid-refractory graft versus host disease. Furthermore, PLX-PAD has successfully completed a Phase II clinical trial for acute respiratory distress syndrome linked to COVID-19 and a Phase I trial for patients with incomplete recovery after bone marrow transplantation. Another key product, PLX-R18, is being developed to aid in the recovery of blood cell production following hematopoietic cell transplantation. Pluri is also collaborating with the National Institutes of Health and the U.S. Department of Defense to create a therapeutic solution for acute radiation syndrome. The company, formerly known as Pluristem Therapeutics Inc., adopted its current name, Pluri Inc., in July 2022.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.56% | -4.80% | -12.18% | -12.10% | -25.14% | +0.09% | -47.70% | -60.28% | -90.66% | -98.06% | -97.87% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+309.8% ★ Q1'26: -60.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+10.8% Q1'26: +40.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,394.3% Q1'26: -2,728.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,659.9% Q1'26: -3,913.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-176.4% Q1'26: -235.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.9% Q1'26: +53.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.56× Q1'26: -1.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
379.0K
est: 386.6K (-2.0%)
|
2.85M
est: 2.84M (+0.3%)
|
50.0K
est: 50.0K (0.0%)
|
54.0K
est: 53.7K (+0.5%)
|
287.0K
est: 65.00M (-99.6%)
|
326.0K
est: 39.76M (-99.2%)
|
1.34M
est: 1.34M (-0.3%)
|
2.40M
2.40M – 2.40M
+79.2% YoY
|
9.46M
9.46M – 9.46M
+294.0% YoY
|
| EBITDA |
-23.19M
est: -232.0K (-9,898.7%)
|
-21.17M
est: -1.70M (-1,143.0%)
|
-24.11M
est: -30.0K (-80,233.2%)
|
-33.35M
est: -32.2K (-103,349.9%)
|
-27.68M
est: -39.00M (+29.0%)
|
-20.23M
est: -23.85M (+15.2%)
|
-21.86M
est: -803.8K (-2,619.6%)
|
-1.44M
-1.44M – -1.44M
-79.2% YoY
|
-5.68M
-5.68M – -5.68M
-294.0% YoY
|
| EBIT |
-25.27M
est: -232.0K (-10,792.8%)
|
-23.32M
est: -1.70M (-1,269.3%)
|
-26.13M
est: -30.0K (-86,957.6%)
|
-35.31M
est: -32.2K (-109,436.8%)
|
-28.04M
est: -39.00M (+28.1%)
|
-20.48M
est: -23.85M (+14.2%)
|
-22.18M
est: -803.8K (-2,658.9%)
|
-1.44M
-1.44M – -1.44M
-79.2% YoY
|
-5.68M
-5.68M – -5.68M
-294.0% YoY
|
| Net Income |
-24.68M
est: -175.34M (+85.9%)
|
-23.25M
est: -151.63M (+84.7%)
|
-26.13M
est: -121.18M (+78.4%)
|
-35.31M
est: -153.83M (+77.0%)
|
-28.32M
est: -63.73M (+55.6%)
|
-20.89M
est: -16.79M (-24.4%)
|
-22.58M
est: -19.03M (-18.6%)
|
-15.89M
-15.89M – -15.89M
+16.5% YoY
|
-11.18M
-11.18M – -11.18M
+29.6% YoY
|
| SGA |
6.46M
est: 11.97M (-46.0%)
|
6.49M
est: 87.91M (-92.6%)
|
11.19M
est: 1.55M (+622.5%)
|
9.16M
est: 1.66M (+450.3%)
|
11.78M
est: 2.01B (-99.4%)
|
10.03M
est: 1.23B (-99.2%)
|
9.98M
est: 41.49M (-76.0%)
|
74.36M
74.36M – 74.36M
+79.2% YoY
|
292.99M
292.99M – 292.99M
+294.0% YoY
|
| EPS |
-28.09
est: -27.67 (-1.5%)
|
-23.38
est: -23.93 (+2.3%)
|
-19.74
est: -19.12 (-3.2%)
|
-22.90
est: -24.27 (+5.7%)
|
-6.18
est: -10.06 (+38.5%)
|
-3.99
est: -2.65 (-50.6%)
|
-3.56
est: -3.00 (-18.5%)
|
-2.51
-2.51 – -2.51
+16.5% YoY
|
-1.76
-1.76 – -1.76
+29.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yaacov Yanay | President, Chief Executive Officer & Director | 558.4K | male |
| Liat Zalts | Chief Financial Officer & Treasurer | 208.4K | female |
| Hagit Gal | General Counsel | — | female |
| Lior Raviv | Chief Technology Officer | — | male |
| Arthur Machlenkin | Chief Scientific Officer | — | — |
| Nofar Glaich-Dabach | Vice President of Human Resources | — | female |
| Ori Shalem | Vice President of Operations & Manufacturing | — | male |
| Orly Amiran | Chief Quality Officer | — | female |
| Nimrod Bar Zvi | Chief Commercial Officer | — | male |
| Efrat Kaduri | Chief Business Development Officer of Pharma | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLUR.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
